Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Evofem Biosciences, Inc. (NEOT) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Evofem Biosciences, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1618835.
Total stock buying since 2014: $58,784,377.
Total stock sales since 2014: $36,975,914.
Total stock option exercises since 2014: $2,366,122.
Insider Buying | Insider Sales | Option Exercises | ||||
---|---|---|---|---|---|---|
Year | Shares | Value | Shares | Value | Shares | Value |
2024 | 0 | $0 | 104 | $4 | 0 | $0 |
2023 | 0 | $0 | 10 | $6 | 0 | $0 |
2022 | 141,000 | $49,773 | 0 | $0 | 0 | $0 |
2021 | 371,663 | $314,549 | 0 | $0 | 0 | $0 |
2020 | 901,743 | $3,117,124 | 18,511,133 | $32,492,013 | 37,500 | $0 |
2019 | 9,314,420 | $41,123,401 | 46,655 | $318,370 | 112,500 | $0 |
2018 | 2,249,653 | $10,251,773 | 0 | $0 | 75,000 | $0 |
2016 | 0 | $0 | 0 | $0 | 16,393 | $18,524 |
2015 | 1,000 | $7,757 | 1,339,949 | $2,075,517 | 21,946 | $70,075 |
2014 | 280,000 | $3,920,000 | 149,286 | $2,090,004 | 266,689 | $2,277,523 |
Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
---|---|---|---|---|---|---|
year-month | Shares | Value | Shares | Value | Shares | Value |
2024-01 | 0 | $0 | 104 | $4 | 0 | $0 |
2023-12 | 0 | $0 | 10 | $6 | 0 | $0 |
2022-05 | 141,000 | $49,773 | 0 | $0 | 0 | $0 |
2021-12 | 200,594 | $75,369 | 0 | $0 | 0 | $0 |
2021-06 | 125,820 | $136,013 | 0 | $0 | 0 | $0 |
2021-03 | 45,249 | $103,167 | 0 | $0 | 0 | $0 |
2020-11 | 16,850 | $36,837 | 0 | $0 | 0 | $0 |
2020-09 | 4,000 | $8,950 | 122,500 | $399,350 | 0 | $0 |
2020-06 | 880,893 | $3,071,337 | 18,277,008 | $31,427,314 | 0 | $0 |
2020-05 | 0 | $0 | 78,090 | $455,710 | 0 | $0 |
2020-04 | 0 | $0 | 1,000 | $4,660 | 0 | $0 |
2020-03 | 0 | $0 | 0 | $0 | 37,500 | $0 |
2020-02 | 0 | $0 | 15,957 | $104,220 | 0 | $0 |
2020-01 | 0 | $0 | 16,578 | $100,759 | 0 | $0 |
2019-12 | 0 | $0 | 31,000 | $224,950 | 37,500 | $0 |
2019-11 | 0 | $0 | 15,000 | $90,100 | 0 | $0 |
2019-09 | 0 | $0 | 0 | $0 | 37,500 | $0 |
2019-06 | 8,888,889 | $40,000,000 | 0 | $0 | 37,500 | $0 |
2019-05 | 0 | $0 | 655 | $3,320 | 0 | $0 |
2019-02 | 425,531 | $1,123,401 | 0 | $0 | 0 | $0 |
2018-11 | 279 | $990 | 0 | $0 | 0 | $0 |
2018-08 | 121,715 | $272,063 | 0 | $0 | 0 | $0 |
2018-07 | 0 | $0 | 0 | $0 | 75,000 | $0 |
2018-05 | 2,127,659 | $9,978,720 | 0 | $0 | 0 | $0 |
Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2024-01-12 | Zhang Yan (CFO) | Sale | 104 | .04 | 4 |
2023-12-21 | Kamdar Kim P. | Sale | 10 | .62 | 6 |
2022-05-27 | Pelletier Saundra L (Chief Executive Officer) | Buy | 141,000 | .35 | 49,773 |
2021-12-20 | File Justin J. (Chief Financial Officer) | Buy | 40,594 | .37 | 15,019 |
2021-12-20 | Fitzpatrick Alexander A (General Counsel and Secretary) | Buy | 25,000 | .39 | 9,725 |
2021-12-20 | Pelletier Saundra L (Chief Executive Officer) | Buy | 135,000 | .38 | 50,625 |
2021-06-18 | Kamdar Kim P. | Buy | 10,000 | 1.17 | 11,650 |
2021-06-14 | O'brien Anthony Stephen | Buy | 8,140 | 1.31 | 10,663 |
2021-06-11 | Rarick Lisa Dale | Buy | 5,000 | 1.20 | 5,990 |
2021-06-11 | Barrans Russell (Chief Commercial Officer) | Buy | 18,180 | 1.14 | 20,725 |
2021-06-10 | File Justin J. (Chief Financial Officer) | Buy | 24,500 | 1.03 | 25,235 |
2021-06-10 | Fitzpatrick Alexander A (General Counsel and Secretary) | Buy | 10,000 | 1.02 | 10,250 |
2021-06-10 | Pelletier Saundra L (Chief Executive Officer) | Buy | 50,000 | 1.03 | 51,500 |
2021-03-09 | Pelletier Saundra L (Chief Executive Officer) | Buy | 45,249 | 2.28 | 103,167 |
2020-11-17 | File Justin J. (Chief Financial Officer) | Buy | 7,760 | 2.17 | 16,839 |
2020-11-17 | Fitzpatrick Alexander A (General Counsel and Secretary) | Buy | 9,090 | 2.20 | 19,998 |
2020-09-11 | Barrans Russell (Chief Commercial Officer) | Buy | 3,000 | 2.08 | 6,240 |
2020-09-10 | Barrans Russell (Chief Commercial Officer) | Buy | 1,000 | 2.71 | 2,710 |
2020-09-08 | Pelletier Saundra L (Chief Executive Officer) | Sale | 122,500 | 3.26 | 399,350 |
2020-06-17 | Rarick Lisa Dale | Buy | 5,250 | 2.99 | 15,697 |
2020-06-15 | Hall William Walmsley | Buy | 5,000 | 2.85 | 14,250 |
2020-06-12 | File Justin J. (Chief Financial Officer) | Buy | 8,500 | 3.14 | 26,690 |
2020-06-12 | Kamdar Kim P. | Buy | 5,000 | 2.94 | 14,700 |
2020-06-05 | Invesco Ltd. (10% Owner) | Buy | 857,143 | 3.50 | 3,000,000 |
2020-06-04 | Link Fund Solutions Ltd (10% Owner) | Sale | 9,138,504 | .23 | 2,101,855 |
2020-06-04 | Acacia Research Corp | Sale | 9,138,504 | 3.21 | 29,325,459 |
2020-05-26 | Invesco Ltd. (10% Owner) | Sale | 73,879 | 5.88 | 434,777 |
2020-05-15 | Invesco Ltd. (10% Owner) | Sale | 3,211 | 5.04 | 16,183 |
2020-05-01 | Culwell Kelly (Chief Medical Officer) | Sale | 1,000 | 4.75 | 4,750 |
2020-04-30 | Culwell Kelly (Chief Medical Officer) | Sale | 1,000 | 4.66 | 4,660 |
2020-03-31 | Lynch Thomas G | Option Ex | 37,500 | .00 | 0 |
2020-02-19 | Barrans Russell (Chief Commercial Officer) | Sale | 14,957 | 6.50 | 97,220 |
2020-02-19 | Culwell Kelly (Chief Medical Officer) | Sale | 1,000 | 7.00 | 7,000 |
2020-01-16 | Barrans Russell (Chief Commercial Officer) | Sale | 1,578 | 6.50 | 10,257 |
2020-01-13 | File Justin J. (Chief Financial Officer) | Sale | 1,648 | 6.00 | 9,888 |
2020-01-13 | Pelletier Saundra L (Chief Executive Officer) | Sale | 3,295 | 6.00 | 19,770 |
2020-01-02 | File Justin J. (Chief Financial Officer) | Sale | 3,352 | 6.05 | 20,279 |
2020-01-02 | Pelletier Saundra L (Chief Executive Officer) | Sale | 6,705 | 6.05 | 40,565 |
2019-12-31 | Lynch Thomas G | Option Ex | 37,500 | .00 | 0 |
2019-12-02 | File Justin J. (Chief Financial Officer) | Sale | 10,000 | 7.16 | 71,600 |
2019-12-02 | Culwell Kelly (Chief Medical Officer) | Sale | 1,000 | 7.35 | 7,350 |
2019-12-02 | Pelletier Saundra L (Chief Executive Officer) | Sale | 20,000 | 7.30 | 146,000 |
2019-11-21 | File Justin J. (Chief Financial Officer) | Sale | 4,900 | 6.00 | 29,400 |
2019-11-21 | Pelletier Saundra L (Chief Executive Officer) | Sale | 10,000 | 6.01 | 60,100 |
2019-11-20 | File Justin J. (Chief Financial Officer) | Sale | 100 | 6.00 | 600 |
2019-09-30 | Lynch Thomas G | Option Ex | 37,500 | .00 | 0 |
2019-06-30 | Lynch Thomas G | Option Ex | 37,500 | .00 | 0 |
2019-06-10 | Invesco Ltd. (10% Owner) | Buy | 2,222,222 | 4.50 | 9,999,999 |
2019-06-10 | Pdl Biopharma, Inc. (10% Owner) | Buy | 6,666,667 | 4.50 | 30,000,001 |
2019-05-21 | Kamdar Kim P. (Director) | Sale | 655 | 5.07 | 3,320 |
2019-02-08 | Invesco Ltd. (10% Owner) | Buy | 425,531 | 2.64 | 1,123,401 |
2018-11-21 | Barrans Russell (Chief Commercial Officer) | Buy | 279 | 3.55 | 990 |
2018-08-21 | Fitzpatrick Alexander A (General Counsel and Secretary) | Buy | 500 | 2.27 | 1,135 |
2018-08-20 | Fitzpatrick Alexander A (General Counsel and Secretary) | Buy | 4,500 | 2.20 | 9,900 |
2018-08-16 | Culwell Kelly (Chief Medical Officer) | Buy | 3,000 | 2.24 | 6,720 |
2018-08-15 | Lynch Thomas G | Buy | 68,929 | 2.33 | 160,604 |
2018-08-14 | Lynch Thomas G | Buy | 31,071 | 2.10 | 65,249 |
2018-08-10 | Barrans Russell (Chief Commercial Officer) | Buy | 3,715 | 1.98 | 7,355 |
2018-08-10 | Pelletier Saundra L (Chief Executive Officer) | Buy | 10,000 | 2.11 | 21,100 |
2018-07-02 | Lynch Thomas G | Option Ex | 75,000 | .00 | 0 |
2018-05-22 | Invesco Ltd. (10% Owner) | Buy | 2,127,659 | 4.69 | 9,978,720 |
2016-06-21 | Demski Martha J (Director) | Option Ex | 16,393 | 1.13 | 18,524 |
2015-12-30 | Nohra Guy P (Other) | Sale | 250,000 | 1.44 | 360,000 |
2015-12-29 | Nohra Guy P (Other) | Sale | 493,654 | 1.53 | 755,290 |
2015-12-28 | Nohra Guy P (Other) | Sale | 54,333 | 1.59 | 86,389 |
2015-12-17 | Knudson Susan A. (Chief Financial Officer) | Sale | 1,005 | 1.26 | 1,266 |
2015-12-17 | Locke Kenneth W (Chief Scientific Officer) | Sale | 598 | 1.26 | 753 |
2015-12-15 | Nohra Guy P (10% Owner) | Sale | 529,261 | 1.44 | 762,135 |
2015-11-18 | Locke Kenneth W (Chief Scientific Officer) | Sale | 6,098 | 8.30 | 50,619 |
2015-11-18 | Locke Kenneth W (Chief Scientific Officer) | Option Ex | 6,098 | 8.30 | 50,619 |
2015-09-18 | Kemmerer Christopher (VP, Pharma Dev & Manufacturing) | Sale | 1,000 | 12.20 | 12,195 |
2015-09-18 | Kemmerer Christopher (VP, Pharma Dev & Manufacturing) | Option Ex | 1,000 | 1.34 | 1,342 |
2015-09-01 | Knudson Susan A. (Chief Financial Officer) | Sale | 3,000 | 11.33 | 33,990 |
2015-09-01 | Knudson Susan A. (Chief Financial Officer) | Option Ex | 3,000 | 1.22 | 3,660 |
2015-08-07 | Kemmerer Christopher (VP, Pharma Dev & Manufacturing) | Sale | 1,000 | 12.88 | 12,880 |
2015-08-07 | Kemmerer Christopher (VP, Pharma Dev & Manufacturing) | Option Ex | 1,000 | 1.22 | 1,220 |
2015-06-12 | Kemmerer Christopher (VP, Pharma Dev & Manufacturing) | Option Ex | 10,848 | 1.22 | 13,234 |
2015-03-19 | Mahaffey George W (President and CEO) | Buy | 1,000 | 7.76 | 7,757 |
2014-11-25 | Gorbachev Maxim (Director) | Buy | 70,000 | 14.00 | 980,000 |
2014-11-25 | Rusnanomedinvest Llc (10% Owner) | Buy | 70,000 | 14.00 | 980,000 |
2014-11-25 | Halak Brian K (10% Owner) | Buy | 70,000 | 14.00 | 980,000 |
2014-11-25 | Halak Brian K (10% Owner) | Option Ex | 262,292 | 8.54 | 2,239,973 |
2014-11-25 | Nohra Guy P (10% Owner) | Buy | 70,000 | 14.00 | 980,000 |
2014-11-25 | Nohra Guy P (10% Owner) | Sale | 149,286 | 14.00 | 2,090,004 |
Insider trading activities including stock purchases, stock sales, and option exercises of NEOT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Evofem Biosciences, Inc. (symbol NEOT, CIK number 1618835) see the Securities and Exchange Commission (SEC) website.